First-in-class immune-modulating small molecule Icaritin in advanced hepatocellular carcinoma: preliminary results of safety, durable survival and immune biomarkers
Abstract Background With poor prognosis and limited treatment options for advanced hepatocellular carcinoma (HCC), development of novel therapeutic agents is urgently needed. This single-arm phase I study sought to assess the safety and preliminary efficacy of icaritin in human as a potential oral i...
Main Authors: | Ying Fan, Shu Li, Xiaoyan Ding, Jian Yue, Jun Jiang, Hong Zhao, Rui Hao, Weiliang Qiu, Kezhen Liu, Ying Li, Shengdian Wang, Limin Zheng, Bin Ye, Kun Meng, Binghe Xu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-03-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12885-019-5471-1 |
Similar Items
-
Nanomedicine‐boosting icaritin-based immunotherapy of advanced hepatocellular carcinoma
by: Yi Lu, et al.
Published: (2022-12-01) -
Icaritin promotes apoptosis and inhibits proliferation by down-regulating AFP gene expression in hepatocellular carcinoma
by: Hui Li, et al.
Published: (2021-03-01) -
Modulation of the Autophagy-Lysosomal Pathway in Hepatocellular Carcinoma Using Small Molecules
by: Yu Geon Lee, et al.
Published: (2020-03-01) -
Investigating the effect of Icaritin on hepatocellular carcinoma based on network pharmacology
by: Zhong Xue, et al.
Published: (2023-05-01) -
Non-coding RNAs in hepatocellular carcinoma: Insights into regulatory mechanisms, clinical significance, and therapeutic potential
by: Qin Han, et al.
Published: (2022-10-01)